Download presentation
Presentation is loading. Please wait.
1
FOUNDER, SCIENTIFIC DIRECTOR
TM ISTVAN PETAK, MD, PHD FOUNDER, SCIENTIFIC DIRECTOR
2
7,6 MILLION 13,1 MILLION 1:4 GLOBOCAN 2008, WHO
3
Which are the drugable gene mutations?
Growth factor Growth Factor Receptor Tyrosin kinases A Mutant Gene Census Nucleus Faulty signal transduction protein Cancer Cell Targeted drug Division
4
Biomedical RESEARCHERS trained in the usa and swiss
Story of kps (2003) Biomedical RESEARCHERS trained in the usa and swiss 1995 => 2002 Dr. ISTVAN PETAK USA Dr. RICHARD SCHWAB SWISS
5
Story of kps (2004) First molecular diagnostics based targeted tHerapy of a LUNG CANCER PATIENT 2003 2004 2009 Schwab Richárd, Peták István, Pintér Ferenc….Kopper László, Kéri György, Pap Ákos J Clin Oncol Oct 20;23(30):
6
MOLECULAR DIAGNOSTIC LABORATORY
7
PATENTED TECHNOLOGY TO ANALYZE SMALL SAMPLES
100% MULTIPLEX XS-dXtm OPTIMIZED DIRECT PCR LCM (ZEISS-PALM)
8
Successful diagnostics in 84 cells
(italian patient) 28 db 56 db EGFR EXON 21 L858R Response to therapy
9
INTERNATIONAL EXPANSION WITH THE SUPPORT OF VENTURE CAPITAL INVESTMENT IN 2012
10
500,000 mutations in 460 cAncer genes
SANGER DATABASE 460 cancer genes 1% of all genes 90% somatic mutations 20% germline mutations 10% show both somatic and germline mutations
11
TARGETED THERAPIES IN PIPELINES
Abbott Astra-Z GSK Lilly Merck Novartis Pfizer Roche Wyeth EGFR x x VEGF/R x x IGF/R x x x cMET x x x x Multi x x x x x x PI3K/mTOR x x x x x RAF x x x MEK x x SRC x x CDK4/ x CHK1 x x Aurorakináz x x x Eg5,kinezin x Tubulin x x PARP x x x BCL2 x IAP x Survivin x HSP90 x x Deacetiláz x Endotelin x x g-szekretáz x x MDM x DKK x 5a-reduktáz x VDA x Bali 2010. Október 6. 11. dia 11
12
5000< CLINICAL TRIALS FOR BREAST CANCER (WWW.CLINICALTRIALS.GOV)
MORE AND MORE BIOMARKER DRIVEN LOOKING FOR SMALL FRACTION OF PATIENTS
13
MOLECULAR TARGETS …50 …. CLINICAL PARAMETERS
14
PIONEERING NEXT GENERATION SEQUENCING IN ONCOLOGY
15
„HeurAA” Heuristic Amplicon Analyzer
PATENTED TECHNOLOGY TO find mutations IN MANY SEQUENCES „HeurAA” Heuristic Amplicon Analyzer
16
Number of genes number 2009 2010 2011 2012
17
TARGETED RESEQUENCING PANELS
58 genes ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL.+ egyedi gének + FISH: EGFR, HER-2, FGFR, ALK, MET Illumina HiSeq™ 2000 platform for 2574 exons representing 176 genes captured using Agilent SureSelect™ 50% acionable mutations MGH's Diagnostic Molecular Pathology lab SNaPshot assay, hotspot mutations in 14 oncogenes 50 to 60 patients per week NEXT: NGS 50 different targets Genomweb September 19, 2012 + in combination with fluorescence in situ hybridization Feri Dia next gen Messechusec 15 gén átállás Ilimuna, roche, Foundation med, diagnostics
18
MOLECULAR GENETICS BASED PERSONALIZED SIGNAL TRANSDUCTION THERAPIES
GENE TEST 58< TARGET 280< TARGETED DRUGS CANCER CELLS
19
ONCOMPASS TM IS A “BLUE OCEAN” SERVICE IN A RAPIDLY GROWING MARKET
OUR COSTUMERS: PATIENTS: THEY WANT ACCESS TO MORE EFFECTIVE AND LESS TOXIC TARGETED THERAPY PHARMA: THEY WANT TO FIND PATIENTS WITH RARE GENETIC PROFILE MATCHING THEIR DRUG PHARMA/CRO: THEY WANT TO RECRUIT PATIENTS WITH RARE GENETIC PROFILE TO ACCELERATE DOCTORS/HOSPITALS: THEY WANT MORE PATIENTS, CLINICAL TRIALS ARE PROFITABLE AND COMPETITIVE PAYERS/INSURANCE: THEY WANT MORE COST EFFECTIVE TREATMENT, THEY WANT MORE PATIENTS IN CLINICAL TRIALS
20
ONCOMPASS TM IS A “BLUE OCEAN” SERVICE
IN A RAPIDLY GROWING MARKET IN THE NEXT 20 YEARS ENGINES OF GROWTH: PATIENTS: THE NUMBER WILL 2X IN THE NEXT 20 YEARS (INCREASE WILL BE FASTER IN ASIA) DRUGS: THE NUMBER OF TARGETED DRUGS WILL 10X GENES: NUMBER OF GENES ANALYZED ON ONE CHIP WILL 10X
21
THANK YOU FOR YOUR KIND ATTENTION!
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.